Agoracom: Small Cap Investment - Zenith Epigenetics - Re: AACR 2018

Zenithepigenetics

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free

Reply New Message

Back To Forum List View

2

Jan 18, 2018 04:07PM

5

Feb 21, 2018 11:38AM

3

Feb 21, 2018 05:45PM

4

Feb 21, 2018 05:52PM

5

Feb 22, 2018 10:34AM

4

Feb 22, 2018 02:25PM

3

Feb 23, 2018 02:54AM

3

Feb 23, 2018 11:14AM

3

Feb 23, 2018 12:41PM

3

Feb 27, 2018 06:33PM

1

Feb 27, 2018 08:43PM

4

Feb 28, 2018 10:42AM

2

Feb 28, 2018 05:41PM

3

Feb 28, 2018 05:57PM

2

Mar 01, 2018 05:17PM

2

Mar 01, 2018 09:35PM

1

Mar 05, 2018 03:13PM

2

Mar 05, 2018 03:59PM

2

Mar 05, 2018 11:08PM

3

Mar 06, 2018 03:46AM

2

Mar 06, 2018 10:13AM

2

Mar 06, 2018 01:15PM

2

Mar 06, 2018 01:24PM

2

Mar 21, 2018 11:36AM

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: AACR 2018

in response to

by

posted on Apr 13, 2018 09:23AM

Log in to use the IP Check tool ^[?]

AACR 2018 kicks off tomorrow in Chicago. April 14-18. Quite a number of BET inhibitor presentations there, including some in the prostate cancer area. Last I heard, Zenith is not presenting. It will still be wise to follow these developments. #AACR2018. If you see or hear anything noteworthy related to BET inhibitors and mCRPC, please share on this board.

BDAZ

3 Recommendations

Loading...

Loading...

Reply New Message

Back To Forum List View

Share

Share

Share

Please to post a reply